Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF): 2014-2025

Historic Depreciation & Amortization (CF) for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to $261,000.

  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) rose 19.18% to $261,000 in Q2 2025 from the same period last year, while for Apr 2025 it was $931,000, marking a year-over-year increase of 14.09%. This contributed to the annual value of $941,000 for FY2025, which is 15.32% up from last year.
  • As of Q2 2025, KalVista Pharmaceuticals' Depreciation & Amortization (CF) stood at $261,000, which was up 14.98% from $227,000 recorded in Q4 2024.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $261,000 during Q2 2025, with a 5-year trough of $193,000 in Q3 2023.
  • For the 3-year period, KalVista Pharmaceuticals' Depreciation & Amortization (CF) averaged around $218,286, with its median value being $219,000 (2024).
  • Data for KalVista Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY increased of 19.18% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $197,000 in 2023, then rose by 15.23% to $227,000 in 2024, then rose by 19.18% to $261,000 in 2025.
  • Its last three reported values are $261,000 in Q2 2025, $227,000 for Q4 2024, and $224,000 during Q3 2024.